Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.42 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6706759 | 0.87 | HRH3 (0.55) | HRH3CYP1A2CYP2D6ALDH1A1MBTD1 | |
| SCHEMBL2587952 | 0.85 | HRH3 (0.52) | HRH3CYP1A2CYP2D6ALDH1A1HRH4 | |
| SCHEMBL21482062 | 0.80 | HRH3 (0.52) | HRH3CYP1A2CYP2D6ALDH1A1MBTD1 | |
| SCHEMBL13467093 | 0.80 | HRH3 (0.71) | HRH3CYP1A2CYP2D6ALDH1A1HRH4 | |
| SCHEMBL17538302 | 0.80 | HRH3 (0.50) | HRH3CYP1A2CYP2D6ALDH1A1MBTD1 | |
| SCHEMBL530048 | 0.80 | HRH3 (0.53) | HRH3CYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL12160184 | 0.79 | CYP1A2 (0.72) | HRH3CYP1A2CYP2D6ALDH1A1HRH4 | |
| SCHEMBL6705583 | 0.77 | HRH3 (0.46) | HRH3CYP1A2CYP2D6ALDH1A1KDM4E | |
| SCHEMBL1935624 | 0.77 | HRH3 (0.68) | HRH3CYP2D6ALDH1A1MBTD1L3MBTL3 | |
| SCHEMBL6562985 | 0.77 | HRH1 (0.48) | HRH3CYP1A2CYP2D6ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | US | claimed |
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | MCHR2, MCHR1, NPY1R | HRH3 254/4885CYP1A2 749/4885CYP2D6 1590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.